NeonMind Biosciences Inc.

12:35 PM EST - NeonMind Biosciences Inc. : Announced that on March 10, 2021 NeonMind engaged Certara®, the global leader in model-informed drug development to provide strategic integrated drug development support for the investigation of NeonMind's psilocybin based drug candidates for the treatment of obesity. "Certara has the expertise, technology and network to further our drug development efforts to help us achieve our goals of progressing psilocybin-based weight loss treatments through the rigorous drug development process," said Rob Tessarolo, President & CEO of NeonMind. "We are assembling world-class R&D capabilities dedicated to creating a dossier of scientific evidence to support regulatory approval for these novel treatments that can positively impact millions of people." NeonMind Biosciences Inc. shares C.NEON are trading up 1.85 percent at $0.28.

Stocks in Play